278
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease

, , , ORCID Icon, &
Pages 927-936 | Published online: 26 Feb 2022

References

  • Perl DP. Neuropathology of Alzheimer’s disease. Mt Sinai J Med. 2010;77(1):32–42. doi:10.1002/msj.20157
  • Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10(9):698–712. doi:10.1038/nrd3505
  • Staffaroni AM, Elahi FM, McDermott D, et al. Neuroimaging in dementia. Semin Neurol. 2017;37(5):510–537. doi:10.1055/s-0037-1608808
  • Valotassiou V, Malamitsi J, Papatriantafyllou J, et al. SPECT and PET imaging in Alzheimer’s disease. Ann Nucl Med. 2018;32(9):583–593. doi:10.1007/s12149-018-1292-6
  • Frisoni GB, Fox NC, Jack CR, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6(2):67–77. doi:10.1038/nrneurol.2009.215
  • Li MH, Wang PJ, Chen SQ, Zhang W, Gao XL. [The comparative study on high field MRI and pathology of Alzheimer’s disease transgenic mice]. Zhonghua Yi Xue Za Zhi. 2011;91(13):876–879. Chinese.
  • Petiet A, Delatour B, Dhenain M. Models of neurodegenerative disease - Alzheimer’s anatomical and amyloid plaque imaging. Methods Mol Biol. 2011;771:293–308.
  • Chamberlain R, Wengenack TM, Poduslo JF, Garwood M, Jack CR. Magnetic resonance imaging of amyloid plaques in transgenic mouse models of Alzheimer’s disease. Curr Med Imaging Rev. 2011;7(1):3–7. doi:10.2174/157340511794653522
  • Mahmoudi M, Serpooshan V, Laurent S. Engineered nanoparticles for biomolecular imaging.. Nanoscale. 2011;3(8):3007–3026. doi:10.1039/c1nr10326a
  • Ma M, Zhan Y, Shen Y, Xia X, Zhang S, Liu Z. Synthesis of amino-group functionalized superparamagnetic iron oxide nanoparticles and applications as biomedical labeling probes. J Nanopart Res. 2011;13:3249–3257. doi:10.1007/s11051-011-0239-9
  • Zhan YQ, Wu J, Xu J, et al. [Study of specially labeling amyloid plaques in vivo in Alzheimer’s transgenic mice with targeted magnetic nano-iron contrast agent]. Zhong Hua Shen Jing Ke Za Zhi. 2011;44:500–503. Chinese.
  • Tjernberg LO, Näslund J, Lindqvist F, et al. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem. 1996;271(15):8545–8548. doi:10.1074/jbc.271.15.8545
  • Carvalho KM, França MS, Camarão GC, Ruchon AF. A new brain metalloendopeptidase which degrades the Alzheimer beta-amyloid 1–40 peptide producing soluble fragments without neurotoxic effects. Braz J Med Biol Res. 1997;30(10):1153–1156. doi:10.1590/S0100-879X1997001000002
  • Torchilin VP. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev. 2008;60(4–5):548–558. doi:10.1016/j.addr.2007.10.008
  • Rao K, Labhasetwar V. Trans-activating transcriptional activator (TAT) peptide-mediated brain drug delivery. J Biomed Nanotechnol. 2006;2:173–185. doi:10.1166/jbn.2006.036
  • Du GH, Liu ZL, Xia X, Jia LH, Zhang SM. Functionalization of Fe3O4 magnetic nanoparticles; 2006.
  • Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150(1):76–85. doi:10.1016/0003-2697(85)90442-7
  • Sadowski M, Pankiewicz J, Scholtzova H, et al. A synthetic peptide blocking the apolipoprotein E/β-amyloid binding mitigates β-amyloid toxicity and fibril formation in vitro and reduces β-amyloid plaques in transgenic mice. Am J Pathol. 2004;165(3):937–948. doi:10.1016/S0002-9440(10)63355-X
  • Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials. 2008;29(33):4429–4438. doi:10.1016/j.biomaterials.2008.08.004
  • Ansciaux E, Burtea C, Laurent S, et al. In vitro and in vivo characterization of several functionalized ultrasmall particles of iron oxide, vectorized against amyloid plaques and potentially able to cross the blood-brain barrier: toward earlier diagnosis of Alzheimer’s disease by molecular imaging. Contrast Media Mol Imaging. 2015;10(3):211–224.
  • André S, Ansciaux E, Saidi E, et al. Validation by magnetic resonance imaging of the diagnostic potential of a heptapeptide-functionalized imaging probe targeted to amyloid-β and able to cross the blood-brain barrier. J Alzheimers Dis. 2017;60(4):1547–1565. doi:10.3233/JAD-170563
  • Wadghiri YZ, Li J, Wang J, et al. Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer’s disease transgenic mice using magnetic resonance microimaging. PLoS One. 2013;8(2):e57097. doi:10.1371/journal.pone.0057097
  • Yang J, Wadghiri YZ, Hoang DM, et al. Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer’s disease transgenic mice using magnetic resonance microimaging. Neuro Image. 2011;55(4):1600–1609. doi:10.1016/j.neuroimage.2011.01.023